# Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

> **NCT06021210** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 80 (estimated)

## Conditions studied

- CMV Infection
- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Letermovir Pill

## Key facts

- **NCT ID:** NCT06021210
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-07
- **Primary completion:** 2024-07-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06021210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06021210, "Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06021210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*